Drug intelligence / Profile preview

MET-002

Development stage: Unknown
Lead developer: Metsera
Modality: Small Molecules, Peptides
Administration: Oral

Overview

MET-002 is an oral peptide therapeutic in development for the treatment of obesity. It acts as a glucagon-like peptide 1 (GLP-1) receptor agonist, a mechanism known to promote weight loss by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying. The drug is being developed by Metsera and represents a new molecular entity within the class of GLP-1 receptor agonists. Clinical trials are ongoing, with Phase I studies currently recruiting participants for obesity indications.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on MET-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MET-002.

Explore the full profile